Bullish Options Activity on Heron Therapeutics Inc Surges After Better Fundamentals

 Bullish Options Activity on Heron Therapeutics Inc Surges After Better Fundamentals

In today’s session Heron Therapeutics Inc (HRTX) registered an unusually high (2,337) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the January, 2017 call, expecting serious HRTX increase. With 2,337 contracts traded and 96224 open interest for the Jan, 17 contract, it seems this is a quite bullish bet. The option with symbol: HRTX170120C00022500 closed last at: $0.7 or 22.2% down. The stock increased 0.30% or $0.05 on November 23, hitting $16.55. About 549,201 shares traded hands. Heron Therapeutics Inc (NASDAQ:HRTX) has declined 28.54% since April 22, 2016 and is downtrending. It has underperformed by 33.95% the S&P500.

Analysts await Heron Therapeutics Inc (NASDAQ:HRTX) to report earnings on February, 17. They expect $-1.07 EPS, down 22.99% or $0.20 from last year’s $-0.87 per share. After $-1.24 actual EPS reported by Heron Therapeutics Inc for the previous quarter, Wall Street now forecasts -13.71% EPS growth.

Heron Therapeutics Inc (NASDAQ:HRTX) Ratings Coverage

Out of 7 analysts covering Heron Therapeutics (NASDAQ:HRTX), 7 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Heron Therapeutics has been the topic of 11 analyst reports since August 3, 2015 according to StockzIntelligence Inc. The firm has “Outperform” rating given on Wednesday, September 23 by Leerink Swann. Brean Capital maintained the stock with “Buy” rating in Monday, August 3 report. Jefferies maintained Heron Therapeutics Inc (NASDAQ:HRTX) on Wednesday, September 23 with “Buy” rating. On Thursday, December 10 the stock rating was initiated by Lake Street with “Buy”. The stock of Heron Therapeutics Inc (NASDAQ:HRTX) earned “Buy” rating by Aegis Capital on Wednesday, October 26. Bank of America initiated Heron Therapeutics Inc (NASDAQ:HRTX) on Wednesday, September 2 with “Buy” rating. Brean Capital maintained Heron Therapeutics Inc (NASDAQ:HRTX) rating on Monday, August 10. Brean Capital has “Buy” rating and $45 price target.

According to Zacks Investment Research, “Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA.”

Heron Therapeutics, Inc. is a biotechnology firm engaged in developing pharmaceutical products for patients suffering from cancer or pain. The company has a market cap of $597.83 million. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. It currently has negative earnings. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

HRTX Company Profile

Heron Therapeutics, Inc., incorporated on February 5, 1987, is a biotechnology company. The Firm is engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology (Biochronomer technology), which can deliver therapeutic levels of a range of otherwise short-acting pharmacological agents over a period of days to weeks with a single subcutaneous injection.

Another recent and important Heron Therapeutics Inc (NASDAQ:HRTX) news was published by Nasdaq.com which published an article titled: “Oversold Conditions For Heron Therapeutics” on October 03, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment